Suppr超能文献

PirB,轴突再生髓磷脂抑制剂Nogo66、MAG和OMgp的第二种受体:对体内再生的影响。

PirB, a second receptor for the myelin inhibitors of axonal regeneration Nogo66, MAG, and OMgp: implications for regeneration in vivo.

作者信息

Filbin Marie T

机构信息

Biology Department, Hunter College, 695 Park Avenue, New York, NY 10065, USA.

出版信息

Neuron. 2008 Dec 10;60(5):740-2. doi: 10.1016/j.neuron.2008.12.001.

Abstract

Inhibitors of axonal regeneration in myelin are believed to be major contributors to the lack of regeneration in the adult CNS. Three of the four known myelin inhibitors, although very different structurally, interact with the same receptor, NgR. However, the absence of NgR has no effect on inhibition of neurite outgrowth in culture, and there is no improvement in CST regeneration in vivo. In a recent issue of Science, a second receptor for these myelin inhibitors was described, PirB, a receptor first described in the immune system. Will PirB be the answer to CST regeneration in vivo?

摘要

髓磷脂中轴突再生的抑制剂被认为是导致成年中枢神经系统缺乏再生能力的主要因素。已知的四种髓磷脂抑制剂中的三种,尽管在结构上差异很大,但都与同一受体NgR相互作用。然而,缺乏NgR对培养物中神经突生长的抑制没有影响,并且在体内皮质脊髓束(CST)再生方面也没有改善。在最近一期的《科学》杂志上,报道了这些髓磷脂抑制剂的第二种受体PirB,它是首次在免疫系统中被描述的一种受体。PirB会是体内CST再生问题的答案吗?

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验